We have located links that may give you full text access.
9B.05: ASSOCIATION OF PLASMA PARATHYROID HORMONE WITH NIGHTTIME BLOOD PRESSURE IN PRIMARY HYPERPARATHYROIDISM-THE "EPLERENONE IN PRIMARY HYPERPARATHYROIDISM" TRIAL.
Journal of Hypertension 2015 June
OBJECTIVE: High parathyroid hormone (PTH) is a cardiovascular risk factor. Elevated plasma PTH levels are independently linked with high nighttime blood pressure (BP) in hypertensive patients. We therefore investigated the association between PTH and nighttime BP in patients with primary hyperparathyroidism (pHPT).
DESIGN AND METHOD: We analyzed patients with pHPT who participated in the "Eplerenone in Primary Hyperparathyroidism" (EPATH) Trial. Blood sampling was performed after an overnight fast and all laboratory parameters were determined immediately after blood sampling. 24-hour ambulatory BP monitoring was performed using a certified device (Mobil-O-Graph, I.E.M., Stolberg, Germany). Patients with regular use of the PTH modifying drug cinacalcet or with a reduced left ventricular ejection fraction <= 45% were excluded.
RESULTS: We enrolled 120 patients (mean age: 66 +/- 10 years, 98 were females [82%]). Median PTH (IQR) was 94 pg/mL (79 - 113), mean systolic and diastolic nighttime BP were 117 +/- 17 mmHg and 68 +/- 10 mmHg, respectively. PTH was directly correlated with mean systolic and mean diastolic nighttime BP (Spearman rho = 0.246, p = 0.007; rho = 0.214, p = 0.019, respectively). In multivariate linear regression analyses adjusted for age, sex, cholesterol, HbA1c, intake of antihypertensive drugs, 25-hydroxy vitamin D and glomerular filtration rate (CKDEPI), PTH remained significantly related to mean systolic nighttime BP (adjusted beta-coefficient = 0.194, p = 0.047), while the relationship with mean diastolic nighttime BP was not significant (beta = 0.260, p = 0.109).
CONCLUSIONS: Plasma PTH was associated with mean systolic nighttime BP in patients with pHPT, independently of potential confounders. These novel data from the EPATH Trial further support the notion that PTH directly interferes with nighttime BP regulation. Whether lowering circulating PTH concentrations reduces the burden of high BP remains to be shown in future studies.
DESIGN AND METHOD: We analyzed patients with pHPT who participated in the "Eplerenone in Primary Hyperparathyroidism" (EPATH) Trial. Blood sampling was performed after an overnight fast and all laboratory parameters were determined immediately after blood sampling. 24-hour ambulatory BP monitoring was performed using a certified device (Mobil-O-Graph, I.E.M., Stolberg, Germany). Patients with regular use of the PTH modifying drug cinacalcet or with a reduced left ventricular ejection fraction <= 45% were excluded.
RESULTS: We enrolled 120 patients (mean age: 66 +/- 10 years, 98 were females [82%]). Median PTH (IQR) was 94 pg/mL (79 - 113), mean systolic and diastolic nighttime BP were 117 +/- 17 mmHg and 68 +/- 10 mmHg, respectively. PTH was directly correlated with mean systolic and mean diastolic nighttime BP (Spearman rho = 0.246, p = 0.007; rho = 0.214, p = 0.019, respectively). In multivariate linear regression analyses adjusted for age, sex, cholesterol, HbA1c, intake of antihypertensive drugs, 25-hydroxy vitamin D and glomerular filtration rate (CKDEPI), PTH remained significantly related to mean systolic nighttime BP (adjusted beta-coefficient = 0.194, p = 0.047), while the relationship with mean diastolic nighttime BP was not significant (beta = 0.260, p = 0.109).
CONCLUSIONS: Plasma PTH was associated with mean systolic nighttime BP in patients with pHPT, independently of potential confounders. These novel data from the EPATH Trial further support the notion that PTH directly interferes with nighttime BP regulation. Whether lowering circulating PTH concentrations reduces the burden of high BP remains to be shown in future studies.
Full text links
Related Resources
Trending Papers
Review article: Recent advances in ascites and acute kidney injury management in cirrhosis.Alimentary Pharmacology & Therapeutics 2024 March 26
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app